Financial Performance & Guidance - Quanterix's Q1 2025 revenue was $30.3 million, a 5% decrease compared to $32.1 million in Q1 2024 [38] - The company's adjusted cash burn was reduced by half, from $19.4 million in Q1 2024 to $9.0 million in Q1 2025 [13, 38] - Quanterix anticipates full year 2025 revenue to be between $120 million and $130 million [43] - The company projects GAAP gross margin between 55% and 59%, and adjusted gross margin between 50% and 54% for 2025 [44] - Quanterix expects adjusted cash burn of $35 to $45 million and total cash burn of $55 to $65 million for 2025 [45] Strategic Initiatives - Quanterix launched 4 new assays in Q1 2025 and expects to launch 15 new assays in 2025 [18] - The company is launching the Simoa ONE platform at the end of 2025, which is expected to be 10x more sensitive [22, 24] - Quanterix is developing tissue/blood complementary biomarker kits with Akoya, expected to launch in 2025 [29] - The equity value of the Akoya transaction decreased by 67%, from $201 million to $66 million [13] Non-GAAP Measures - Adjusted EBITDA margin was -37.4% in Q1 2025, compared to -25.4% in Q1 2024 [38, 49]

Financial Data and Key Metrics Changes - Quanterix reported revenue of $35.2 million for Q4 2024, an 11% increase year-over-year [10][28] - Non-GAAP gross margin improved to 57.7%, up 300 basis points from the previous year [11][31] - Cash usage declined by 31% to $4.4 million in Q4 2024 [11] Business Line Data and Key Metrics Changes - Accelerator lab revenue reached $8.6 million, a 22% increase driven by clinical trial testing services [29] - Consumable revenue remained flat at $17.4 million as customers transitioned to Advantage PLUS assays [29] - Instrument revenue decreased by 7% to $3.1 million but increased by 29% sequentially [30] Market Data and Key Metrics Changes - North America led revenue growth with a 17% increase, while Europe grew by 11% and Asia-Pacific declined by 6% for the full year [35] - The customer mix for the year was approximately 54% pharma and 46% academia [34] Company Strategy and Development Direction - The company aims to grow its leadership in neurology and expand into immunology and oncology markets through the Simoa ONE platform and the acquisition of Akoya Biosciences [15][20] - Quanterix plans to build a global diagnostic testing infrastructure for Alzheimer's disease, having added 12 partners to its network [17][18] - The company expects to achieve $40 million in operating synergies from the Akoya acquisition by 2026 [23][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the Accelerator business despite market volatility, citing a strong pipeline and diverse customer base [26][52] - The company anticipates a revenue range of $140 million to $146 million for 2025, reflecting a growth of 2% to 6% [40] - Management noted that 20% to 25% of annual revenues are tied to U.S. academic customers, which are expected to decline by 10% in 2025 [41] Other Important Information - The company ended Q4 2024 with $291.7 million in cash and equivalents [36] - Adjusted EBITDA was negative $23.6 million in 2024, compared to negative $19 million in 2023 [38] Q&A Session Summary Question: Impact of NIH academic government on revenue - Management acknowledged the pressure from NIH and indicated that the academic market is experiencing paralysis, affecting decision-making and spending [58][76] Question: Confidence in second half recovery - Management expressed confidence in the Accelerator business, citing a strong pipeline and expected larger projects to materialize in the second half of the year [52][75] Question: Details on validation phase with hospitals - Management confirmed that 10 hospitals are in the validation phase, with some actively in contract negotiations [54] Question: Concerns about the Akoya merger - Management emphasized the long-term value of the Akoya merger, focusing on recurring revenues and synergies [60][82] Question: Revenue guidance and academic market assumptions - Management indicated that the guidance incorporates expected declines in the academic market and potential upside if funding improves [77][88] Question: Simoa ONE launch impact - Management expects the Simoa ONE platform to launch at the end of 2025, expanding the addressable market in immunology and oncology [67][70] Question: Growth expectations outside the U.S. - Management anticipates low double-digit to high single-digit growth outside the U.S., aligned with overall expectations for 2024 [103]

Financial Performance & Guidance - Quanterix reported Q4 2024 revenue of $35.2 million, an 11% increase compared to $31.5 million in Q4 2023 [25] - The company's full year 2024 revenue reached $137.4 million, a 12% increase from $122.4 million in 2023 [28] - Quanterix anticipates full year 2025 revenue to be between $140 million and $146 million, representing a 2% to 6% growth [36] - The company projects cash usage of $55 million to $65 million for 2025, including $35 million to $45 million for operations and $20 million for the EMISSION acquisition [38] Strategic Initiatives & Acquisitions - Quanterix is expanding its addressable market with the Simoa ONE platform, targeting a $2 billion+ immunology segment [14, 19] - The acquisition of Akoya is expected to significantly expand Quanterix's addressable market to $5 billion [14, 24] - The combined revenue of Quanterix and Akoya is approximately $220 million [24] - Quanterix expects to achieve cash flow breakeven in 2026, which the Akoya merger would expedite [14] Product Development & Innovation - Quanterix launched 20 new assays, including 13 in Neurology and 7 in Immunology [16] - The company is developing the Simoa ONE platform, which is up to 10x more sensitive than current SIMOA technology [19] - Quanterix is building a global infrastructure for Alzheimer's Disease (AD) testing, with a $20 million investment over 2024 and 2025 [14, 22]